Recent advances in optical imaging technologies for the detection of bladder cancer

https://doi.org/10.1016/j.pdpdt.2018.10.009Get rights and content

Highlights

  • White-light cystoscopy still has some limitations in diagnosing bladder cancer.

  • Optical imaging can be used as an adjunctive modality for tumor diagnostic.

  • There are three broad categories of imaging technologies based on the field of view.

  • Some technologies have been implemented and increase detection rate.

  • Combination of several modalities improves the diagnostic accuracy.

Abstract

White-light cystoscopy (WLC) is the diagnostic standard for the detection of bladder cancer (BC). However, the detection of small papillary and subtle flat carcinoma in situ lesions is not always possible with WLC. Several adjunctive optical imaging technologies have been developed to improve BC detection and resection. Photodynamic diagnosis, which requires the administering of a photoactive substance, has a higher detection rate than WLC for the detection of BC. Narrow-band imaging provides better visualization of tumors by contrast enhancement between normal mucosa and well-vascularized lesions. A technology called confocal laser endomicroscopy can be used to obtain detailed images of tissue structure. Optical coherence tomography is a high-resolution imaging process that enables noninvasive, real-time, and high-quality tissue images. Several other optical imaging technologies are also being developed to assist with the detection of BC. In this review, we provide an overview of the strengths and weaknesses of these imaging technologies for the detection of BC.

Introduction

Bladder cancer (BC) is a malignancy affecting the urothelium of the bladder [1]. When considering both genders, BC is the 11th most prevalent malignancy in the world [2]. It affects men, three to four times more than women [3]. Its incidence is rapidly increasing, especially in developing countries. In the last decade, there has been approximately a 15% increment in the incidence of BC. Transitional cell carcinoma (TCC) is the most common histological type [4]. An estimated 76,960 new cases and 16,390 deaths from BC have occurred worldwide in 2016 [5].

Approximately 75–85% of newly diagnosed BC belong to the nonmuscle invasive bladder cancer (NMIBC) group (BC invasion degree is shown in Fig. 1), and in most cases, transurethral resection of the bladder tumor (TURBT) with white-light cystoscopy (WLC) is the choice of treatment [3,[5], [6], [7]]. However, 50–70% of cases recur and 10–30% progress to a higher grade and staging [8]. In most cases, the recurrence is owing to incomplete tumor excision during TURBT with WLC [8,9]. Incomplete tumor excision during TURBT increases the rate of early re-TURBT and recurrence at the first follow-up cystoscopy by three times [10]. WLC often fails to detect small papillary and subtle flat carcinoma in situ (CIS) lesions, leading to progression and more invasive lesions [9]. WLC has low sensitivity for the detection of CIS, which is only 50% [8]. Therefore, more efficient methods are needed to detect CIS.

Several technologies have emerged with the goal to improve BC detection and resection [11]. Optical diagnosis involves light-based tissue imaging [12]. It is used as an adjunctive modality for tumor diagnosis rather than replacing WLC [13]. There are three broad categories of imaging technologies related to their field of view, i.e., macroscopic, microscopic, and molecular imaging [11,[13], [14], [15], [16]]. In this paper, we review the latest literature reports of adjunctive optical imaging technologies for the detection of BC.

Section snippets

Photodynamic diagnosis

Photodynamic diagnosis (PDD) is able to detect BC using fluorescent enhancement [[17], [18], [19]]. PDD utilizes photoactive substances that preferentially accumulate approximately 20 times more in neoplastic tissue than in healthy tissue [18]. Intravesical administration of the photoactive substances demonstrates a better safety profile than oral administration [6]. Currently, hexaminolevulinate (HAL) and 5-aminolaevulinic acid (5-ALA) are the most commonly used photoactive substances [1,6,12

Narrow-band imaging

Narrow-band imaging (NBI) is an imaging technique that does not require the use of photoactive substances [14,15]. However, NBI cannot be used to determine the infiltration status and tumor grade [19]. Table 1 shows a comparison between NBI and PDD. NBI is produced by filtering of a white light source into two wavelengths, blue (415 nm) and green bands (540 nm) [13,16,33]. Hemoglobin preferentially absorbs these wavelengths, which makes the submucosal blood vessels and capillaries more visible [

Confocal laser endomicroscopy

Confocal laser endomicroscopy (CLE) couples the systems of confocal microscopy with those of fibreoptics [11,14]. CLE employs a fiber-optic bundle that transmits 488 nm laser light. CLE also uses fluorescein as the contrast agent to provide real-time, microscopic, in vivo histopathologic information [13,15]. Currently, the available flexible CLE probe can pass through standard cystoscopes with a diameter of 0.85–2.6 mm [11,13]. CLE has a high resolution (2–5 μm) with a 240 μm penetration depth [

Optical coherence tomography

Optical coherence tomography (OCT) is a noninvasive real-time microscopic imaging technique [13]. OCT is comparable to B-mode ultrasonography. The difference between these two modalities is that OCT uses near-infrared wavelength light (890–1300 nm) to produce an image [12,14,19]. OCT images are satisfactory for the detection of most BCs with an axial resolution as high as 1 μm, normally approximately 10–20 μm lateral resolution, and up to 2 mm penetration depth [13,19,51]. OCT uses elastic

Raman spectroscopy

Raman spectroscopy (RS) is an endomicroscopic technology that can be used to analyze the tissue’s molecular components and does not require any photoactive substances [13,15,19]. RS utilizes the Raman effect, which analyzes the inelastic photon scattering after its interaction with intramolecular bonds [12,19]. Infrared light (785–845 nm) is employed to stimulate the intrinsic chemical bonds for creating an optical difference [19].

RS can distinguish the healthy bladder wall layers, assess

Molecular imaging

Molecular imaging is a type of imaging that combines optical imaging and intravesical instillation of fluorescent-labeled components (i.e., peptides, antibodies, and other elements) [19]. These molecular contrast agents allow tumor-specific visualization and decrease the false-positive result caused by inflammatory lesions [14]. A recent study used intravesical fluorescently labeled CD47 antibody (anti-CD47) to successfully demonstrate ex vivo endoscopic molecular imaging of BC using CLE and

Other technologies

Other advanced imaging techniques are being developed to improve BC diagnosis and treatment, such as endocystocopy, multiphoton microscopy (MPM), scanning fiber endoscopy (SFE), ultraviolet (UV) autofluorescence, virtual cystoscopy (VC), photoacoustic imaging (PAI), and coherent anti-Stokes Raman scattering (CARS) which will be discussed below.

Endocystoscopy is a novel modality that provides an ultrahigh magnification image (×450–1125). It is a catheter-type device that can be passed through a

Future direction

The combination of imaging modalities harbors the potential to increase diagnostic accuracy. Macroscopic imaging (PDD, NBI) can be utilized to recognize lesions of interest, whereas microscopic imaging (CLE, OCT) could provide the grading or staging information through high-resolution tissue characterization [11]. Schmidbauer et al. found that the combination of PDD and OCT significantly increased per-patient specificity from 62.5% to 87.5% compared with PDD alone [54]. In another study, the

Conclusion

Clinical under staging of invasive BC remains a significant challenge. Technological advances in optical imaging have the potential to improve the detection and treatment of BC. However, all these technological advances are operator-dependent, and their use heavily depends on the experience of the operating doctor. There are only two optical imaging techniques, PDD and NBI, that are already implemented in a clinical setting. Endomicroscopic technologies are still being studied. Further study is

Funding

This study did not receive a grant from any funding agencies.

Declarations of interest

None.

Acknowledgement

None.

References (60)

  • J. Schmidbauer et al.

    Improved detection of urothelial carcinoma in situ with hexaminolevulinate fluorescence cystoscopy

    J. Urol.

    (2004)
  • S. Denzinger et al.

    Clinically relevant reduction in risk of recurrence of superficial bladder cancer using 5-aminolevulinic acid-induced fluorescence diagnosis: 8-year results of prospective randomized study

    Urology

    (2007)
  • D.I. Daniltchenko et al.

    Long-term benefit of 5-aminolevulinic acid fluorescence assisted transurethral resection of superficial bladder cancer: 5-year results of a prospective randomized study

    J. Urol.

    (2005)
  • M. Kriegmair et al.

    Transurethral resection for bladder cancer using 5-aminolevulinic acid induced fluorescence endoscopy versus white light endoscopy

    J. Urol.

    (2002)
  • M. Burger et al.

    Photodynamic diagnostics and noninvasive bladder cancer: is it cost-effective in long-term application? A Germany-based cost analysis

    Eur. Urol.

    (2007)
  • H.H. Herr

    Narrow band imaging cystoscopy

    Urol. Oncol. Semin. Orig. Investig.

    (2011)
  • A. Naselli et al.

    A randomized prospective trial to assess the impact of transurethral resection in narrow band imaging modality on non-muscle-invasive bladder cancer recurrence

    Eur. Urol.

    (2012)
  • S. Naito et al.

    The clinical research office of the endourological society (CROES) multicentre randomised trial of narrow band imaging–assisted transurethral resection of bladder tumour (TURBT) versus conventional white light imaging–assisted TURBT in primary non–muscle

    Eur. Urol.

    (2016)
  • G. Chen et al.

    Applying narrow-band imaging in complement with white-light imaging cystoscopy in the detection of urothelial carcinoma of the bladder

    Urol. Oncol. Semin. Orig. Investig.

    (2013)
  • G.A. Sonn et al.

    Optical biopsy of human bladder neoplasia with in vivo confocal laser endomicroscopy

    J. Urol.

    (2009)
  • B. Hermes et al.

    Visualization of the basement membrane zone of the bladder by optical coherence tomography: feasibility of noninvasive evaluation of tumor invasion

    Urology

    (2008)
  • S.P. Lerner et al.

    Optical coherence tomography as an adjunct to white light cystoscopy for intravesical real-time imaging and staging of bladder cancer

    Urology

    (2008)
  • J. Schmidbauer et al.

    Fluorescence cystoscopy with high-resolution optical coherence tomography imaging as an adjunct reduces false-positive findings in the diagnosis of urothelial carcinoma of the bladder

    Eur. Urol.

    (2009)
  • C. Schäfauer et al.

    Detection of bladder urothelial carcinoma using in vivo noncontact, ultraviolet excited autofluorescence measurements converted into simple color coded images: a feasibility study

    J. Urol.

    (2013)
  • D. Drejer et al.

    Clinical relevance of narrow-band imaging in flexible cystoscopy: the DaBlaCa-7 study

    Scand. J. Urol.

    (2017)
  • W. Kang et al.

    Narrow band imaging-assisted transurethral resection reduces the recurrence risk of non-muscle invasive bladder cancer: a systematic review and meta-analysis

    Oncotarget

    (2017)
  • R. Umbas et al.

    Urologic cancer in Indonesia

    Jpn. J. Clin. Oncol.

    (2015)
  • S. Yoshida et al.

    DWI as an imaging biomarker for bladder cancer

    Am. J. Roentgenol.

    (2017)
  • P. Kutwin et al.

    Photodynamic diagnosis and narrow-band imaging in the management of bladder cancer: a review

    Photomed. Laser Surg.

    (2017)
  • K. Tatsugami et al.

    Evaluation of narrow-band imaging as a complementary method for the detection of bladder cancer

    J. Endourol.

    (2010)
  • Cited by (0)

    View full text